首页> 外文期刊>Journal of Hepatology: The Journal of the European Association for the Study of the Liver >Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors.
【24h】

Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors.

机译:干扰素单一疗法对日本394例感染丙型肝炎病毒基因型2a的初次连续病例的疗效:病毒,宿主和干扰素治疗相关因素三方相互作用的结果是治疗效果。

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND/AIMS: The mechanism of variable response to interferon (IFN) monotherapy in patients infected with HCV genotype 2a is still unclear. Here we investigated the response in a large group of patients infected with genotype 2a. METHODS: We evaluated 394 consecutive non-cirrhotic naive patients infected with genotype 2a who received IFN monotherapy for 24 weeks, including initial aggressive induction therapy. Of these, 97 were also evaluated for early viral kinetics in serum and treatment efficacy. RESULTS: The overall sustained response (SR) rate was 68.3% (viral load <1.0 Meq/ml (82.4%); >/=1.0 (52.4%)). Multivariate analysis identified five independent factors associated with SR; viral load <1.0 Meq/ml, total IFN dose > or =700 million units, hepatocyte steatosis none or mild, albumin > or =3.9 g/dl, and alanine aminotransferase > or =75 IU/l. The kinetic study showed that serum viral clearance at < or =1 week was the best predictor of SR, and persistence at > or = 4 weeks was a predictor of non-SR. CONCLUSIONS: Our study suggests that viral, host and IFN treatment-related factors determine the response to IFN monotherapy in patients infected with HCV genotype 2a. Further, we report that IFN monotherapy is very effective for patients with genotype 2a, especially for those with low viral load; and that early viral kinetics is useful as a predictor of the response.
机译:背景/目的:HCV基因型2a感染的患者对干扰素(IFN)单药治疗的可变反应机制仍不清楚。在这里,我们调查了一大批感染基因型2a的患者的反应。方法:我们评估了394名连续2个月接受2a基因型感染的非肝硬化幼稚患者,这些患者接受了IFN单药治疗24周,包括最初的积极诱导治疗。其中,还对97个血清和病毒的早期病毒动力学进行了评估。结果:总体持续反应(SR)率为68.3%(病毒载量<1.0 Meq / ml(82.4%);> / = 1.0(52.4%))。多变量分析确定了与SR相关的五个独立因素。病毒载量<1.0 Meq / ml,总IFN剂量>或= 7亿单位,肝细胞脂肪变性无或轻度,白蛋白>或= 3.9 g / dl,丙氨酸转氨酶>或= 75 IU / l。动力学研究表明,<或= 1周时血清病毒清除率是SR的最佳预测指标,而>或= 4周时的持久性则是非SR的预测指标。结论:我们的研究表明,病毒,宿主和与IFN治疗相关的因素决定了HCV基因型2a感染患者对IFN单药治疗的反应。此外,我们报道了IFN单药治疗对基因型2a的患者非常有效,尤其是对于那些病毒载量低的患者。早期的病毒动力学可以作为反应的预测因子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号